SUBSCRIBE
SUBSCRIBE

MAIA Biotechnology

IN THE PRESS
Drug Development
MAIA Biotechnology Accelerates Enrollment in THIO-101 Phase II Clinical Trial as Efficacy Is Observed in Dosed Patients
October 10, 2023
 · 
6 min read
BioMidwest
MAIA Biotechnology Announces Potent Anticancer Activity of THIO in Gliomas
October 10, 2023
 · 
5 min read
Drug Development
MAIA Biotechnology Announces FDA Clearance of IND Application for THIO, a First-in-Class Telomere Targeting Agent for the Treatment of Non-Small Cell Lung Cancer
October 3, 2023
 · 
6 min read
BioMidwest
MAIA Biotechnology Announces Share Repurchase Program
September 28, 2023
 · 
4 min read
Load More
JOBS